GNFT.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 11:35):

Stats
Today's Volume	95 311.00
Average Volume	115 398
Market Cap	159.00M
EPS	€0 ( 2024-04-03 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.52
ATR14	€0.0120 (0.38%)

Volume Correlation

Long: 0.20 (neutral)

Short: 0.46 (neutral)

Signal:(41.285) Neutral

Genfit SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genfit SA Correlation - Currency/Commodity

0.18
( neutral )

-0.04
( neutral )

0.00
( neutral )

-0.19
( neutral )

0.38
( neutral )

Genfit SA Financials

Annual	2023
Revenue:	€28.57M
Gross Profit:	€28.22M (98.81 %)
EPS:	€-0.580

FY	2023
Revenue:	€28.57M
Gross Profit:	€28.22M (98.81 %)
EPS:	€-0.580

FY	2022
Revenue:	€20.20M
Gross Profit:	€19.95M (98.77 %)
EPS:	€-0.480

FY	2021
Revenue:	€80.07M
Gross Profit:	€0.00 (0.00 %)
EPS:	€0.641

Financial Reports:

No articles found.

Genfit SA

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.